Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.75 |
| ▸ | NPC1 | O15118 | 4/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.66 |
| ▸ | RELA | Q04206 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058359 | 0.88 | KMT2A (0.96) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL10199571 | 0.87 | NPC1 (0.67) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4257440 | 0.86 | NPC1 (0.81) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30048093 | 0.86 | NPC1 (0.81) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11474161 | 0.86 | KMT2A (0.79) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9067770 | 0.86 | KMT2A (1.00) | MEN1KMT2ANPC1RAB9APKM | |
| SCHEMBL7822889 | 0.85 | MEN1 (0.78) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7234090 | 0.85 | NPC1 (0.65) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2076281 | 0.85 | HPSE (0.72) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL82305 | 0.84 | RAB9A (1.00) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321766-B1 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160096832-A1 | KINASE INHIBITORS | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2012041987-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096832-A1 | KINASE INHIBITORS | ABL1, LCK, ERBB2 | MEN1 2293/4885KMT2A 1569/4885NPC1 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.